Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Rating of “Moderate Buy” from Analysts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has earned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $41.7778.

A number of brokerages have issued reports on TEVA. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Piper Sandler reiterated an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Finally, Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th.

Teva Pharmaceutical Industries Stock Down 2.3%

Shares of TEVA opened at $34.51 on Thursday. The firm has a market cap of $39.68 billion, a P/E ratio of 25.95, a price-to-earnings-growth ratio of 3.60 and a beta of 0.86. Teva Pharmaceutical Industries has a 12-month low of $14.99 and a 12-month high of $37.35. The company’s 50-day moving average price is $32.45 and its 200 day moving average price is $31.45. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. On average, sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.36 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the business’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the completion of the transaction, the executive vice president directly owned 172,184 shares of the company’s stock, valued at approximately $6,131,472.24. The trade was a 47.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Richard D. Francis sold 20,025 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $634,191.75. Following the transaction, the chief executive officer directly owned 1,170,639 shares of the company’s stock, valued at approximately $37,074,137.13. This represents a 1.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 491,524 shares of company stock valued at $16,789,555. 0.54% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Avidity Partners Management LP grew its position in shares of Teva Pharmaceutical Industries by 7.9% during the first quarter. Avidity Partners Management LP now owns 450,100 shares of the company’s stock worth $13,557,000 after buying an additional 32,800 shares in the last quarter. Alpine Woods Capital Investors LLC boosted its holdings in Teva Pharmaceutical Industries by 98.3% in the first quarter. Alpine Woods Capital Investors LLC now owns 29,424 shares of the company’s stock valued at $886,000 after purchasing an additional 14,587 shares in the last quarter. Glenmede Trust Co. NA boosted its holdings in Teva Pharmaceutical Industries by 486.3% in the first quarter. Glenmede Trust Co. NA now owns 53,377 shares of the company’s stock valued at $1,608,000 after purchasing an additional 44,273 shares in the last quarter. Axiom Investment Management LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at approximately $965,000. Finally, Western Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at approximately $43,000. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.